Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 1, 2009, Pages 234-241

  Drüeke, Tilman B ^a   Ritz, Eberhard ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM ION; CALCIUM SENSING RECEPTOR; CINACALCET; DOXERCALCIFEROL; FETUIN A; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE; DRUG DERIVATIVE; NAPHTHALENE DERIVATIVE;

ARTERY CALCIFICATION; AUTOSOMAL DOMINANT DISORDER; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DYSPEPSIA; EXTRACELLULAR CALCIUM; GASTROINTESTINAL TOXICITY; HEMODIALYSIS; HETEROZYGOTE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; VITAMIN D DEFICIENCY; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; DRUG POTENTIATION; HYPERPARATHYROIDISM; METABOLISM; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANIMALS; CALCIUM; DRUG THERAPY, COMBINATION; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME; VITAMIN D;

EID: 64049106961     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04520908     Document Type: Review

References (98)

1. 2+-sensing receptor from bovine parathyroid. Nature 366: 575-580, 1993
2. Han S, Tang R, Anderson LK, Woerner TE, Pei ZM: A cell surface receptor mediates extracellular Ca(2+) sensing in guard cells. Nature 425: 196-200, 2003 (Pubitemid 37150900)
3. Brown EM, MacLeod RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239-297, 2001
4. Hubbard PC, Ingleton PM, Bendell LA, Barata EN, Canario AV: Olfactory sensitivity to changes in environmental [Ca(2+)] in the freshwater teleost Carassius auratus: An olfactory role for the Ca(2+)-sensing receptor? J Exp Biol 205: 2755-2764, 2002
5. Smajilovic S, TfeltHansen J: Calcium acts as a first messenger through the calcium- sensing receptor in the cardiovascular system. Cardiovasc Res 75: 457-467, 2007 (Pubitemid 47080961)
6. Brown EM: The calcium-sensing receptor: Physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 45: 139-167, 2007
7. Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, Fontilla-Poole M, Mays RW, Brunden KR, Harrington JJ, Quarles LD: Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem 280: 40201-40209, 2005 (Pubitemid 41779157)
8. Chou YH, Brown EM, Levi T, Crowe G, Atkinson AB, Arnqvist HJ, Toss G, Fuleihan GE, Seidman JG, Seidman CE: The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. Nat Genet 1: 295-300, 1992
9. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG: Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303, 1993 (Pubitemid 2030445)
10. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall- Taylor P, Brown EM, Thakker RV: A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335: 1115-1122, 1996 (Pubitemid 26330965)
11. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, Seidman JG: Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 8: 303-307, 1994 (Pubitemid 24978004)
12. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M, Planelles G, Dechaux M, Miller RT, Antignac C: Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 13: 2259-2266, 2002 (Pubitemid 34925236)
13. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T: Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360: 692-694, 2002 (Pubitemid 35232341)
14. Steddon S, Cunningham J: Calcimimetics and calcilytics - Fooling the calcium receptor. Lancet 365: 2237-2239, 2005 (Pubitemid 40853917)
15. Nemeth EF, Steffey ME, Fox J: The parathyroid calcium receptor: A novel therapeutic target for treating hyperparathyroidism. Pediatr Nephrol 10: 275-279, 1996
16. Geibel J, Sritharan K, Geibel R, Geibel P, Persing JS, Seeger A, Roepke TK, Deichstetter M, Prinz C, Cheng SX, Martin D, Hebert SC: Calcium-sensing receptor abrogates secretagogue-induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction. Proc Nat Acad Sci USA 103: 9390-9397, 2006 (Pubitemid 43955837)
17. Levi R, Ben-Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Many T, Silver J: Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: Correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 17: 107-112, 2006
18. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15: 2579-2587, 2004 (Pubitemid 41103364)
19. Rodriguez ME, Almaden Y, Canadillas S, Canalejo A, Siendones E, Lopez I, Aguilera-Tejero E, Martin D, Rodriguez M: The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 292: F1390-F1395, 2007 (Pubitemid 46701865)
20. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100: 2977-2983, 1997 (Pubitemid 28022834)
21. Colloton M, Shatzen E, Miller G, StehmanBreen C, Wada M, Lacey D, Martin D: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67: 467-476, 2005 (Pubitemid 40139838)
22. Ivanovski O, Nikolov I, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Said K, Lacour B, Drueke TB, Massy ZM: The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2009 (in press)
23. Mizobuchi M, Ogata H, Hatamura I, Saji F, Koiwa F, Kinugasa E, Koshikawa S, Akizawa T: Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun 362: 11-16, 2007 (Pubitemid 47296286)
24. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448-453, 1998 (Pubitemid 28097862)
25. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M: Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17: 795-804, 2006
26. Lopez I, Mendoza FJ, AguileraTejero E, Perez J, Guerrero F, Martin D, Rodriguez M: The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73: 300-307, 2008
27. Odenwald T, Nakagawa K, Hadtstein C, Roesch F, Gohlke P, Ritz E, Schaefer F, Schmitt CP: Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 17: 655-662, 2006
28. Ogata H, Ritz E, Odoni G, Amann K, Orth SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14: 959-967, 2003 (Pubitemid 36359277)
29. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML: Calcimimetic R-568 or calcitriol: Equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294: F748-757, 2008
30. Marz W, Seelhorst U, Wellnitz B, Tiran B, Obermayer- Pietsch B, Renner W, Boehm BO, Ritz E, Hoffmann MM: Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality. J Clin Endocrinol Metab 92: 2363-2369, 2007 (Pubitemid 46997147)
31. Hough TA, Bogani D, Cheeseman MT, Favor J, Nesbit MA, Thakker RV, Lyon MF: Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. Proc Natl Acad Sci USA 101: 13566-13571, 2004 (Pubitemid 39238443)
32. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004 (Pubitemid 38477776)
33. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1-201, 2003
34. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB: K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73: 771-777, 2008 (Pubitemid 351323258)
35. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19: 405-412, 2008 (Pubitemid 351240662)
36. Cantor T: Parathyroid hormone assay drift: An unappreciated problem in dialysis patient management. Semin Dial 18: 359-364, 2005
37. Drueke TB, Fukagawa M: Whole or fragmentary information on parathyroid hormone? Clin J Am Soc Nephrol 2: 1106-1107, 2007
38. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC: Variation in serum and plasma PTH levels in secondgeneration assays in hemodialysis patients: A cross-sectional study. Am J Kidney Dis 51: 987-995, 2008 (Pubitemid 351711603)
39. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, LawsonBody E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 70: 345-350, 2006 (Pubitemid 44086584)
40. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M: The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 5644-5649, 2003 (Pubitemid 38033028)
41. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13: 1017-1024, 2002 (Pubitemid 34274098)
42. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D: Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90: 135-141, 2005 (Pubitemid 40116646)
43. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20: 2186-2193, 2005 (Pubitemid 41510096)
44. de Francisco AL, Izquierdo M, Cunningham J, Pinera C, Palomar R, Fresnedo GF, Amado JA, Unzueta MG, Arias M: Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant 23: 2895-2901, 2008
45. Valle C, Rodriguez M, Santamaria R, Almaden Y, Rodriguez ME, Canadillas S, Martin-Malo A, Aljama P: Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 2008 (in press1)
46. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium. J Clin Invest 83: 1349-1355, 1989 (Pubitemid 19113052)
47. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, Slatopolsky E: Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 270: F454-F460, 1996 (Pubitemid 126758433)
48. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM: Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840-853, 2007 (Pubitemid 351664426)
49. Brown AJ, Finch J, Slatopolsky E: Differential effects of 19-nor-1,25-dihydroxyvitamin D-2 and 1,25-dihydroxyvitamin D-3 on intestinal calcium and phosphate transport. J Lab Clin Med 139: 279-284, 2002 (Pubitemid 34577479)
50. Heaney RP, Barger-Lux MJ, Dowell MS, Chen TC, Holick MF: Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 82: 4111-4116, 1997
51. Hamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358-363, 1995
52. Ritz E, Küster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, Heidland A: Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicenter trial). Nephrol Dial Transplant 10: 2228-2234, 1995 (Pubitemid 26033434)
53. Brandi L, Daugaard H, Egsmose D, Tvedegaard E, Nielsen PK, Olgaard K: Intermittent intravenous followed by intermittent oral 1a(OH)D3 treatment of secondary hyperparathyroidism in uraemia. J Intern Med 239: 353-360, 1996 (Pubitemid 26106487)
54. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 1427-1432, 1998 (Pubitemid 28354552)
55. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-2143, 1984 (Pubitemid 15197358)
56. Tan AU, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW: Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51: 317-323, 1997
57. Hosaka K, Kazama JJ, Yamamoto S, Ito Y, Iino N, Maruyama H, Saito A, Narita I, Gejyo F: Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism. J Bone Miner Metab 26: 185-190, 2008 (Pubitemid 351317135)
58. Cannata-Andia JB: Adynamic bone and chronic renal failure: An overview. Am J Med Sci 320: 81-84, 2000 (Pubitemid 30665225)
59. Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 73: 1345-1354, 2008 (Pubitemid 351770492)
60. Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22: 860-866, 2007 (Pubitemid 351339746)
61. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19: 1509-1519, 2008
62. Locatelli F, Cannata-Andia JB, Drueke TB, Horl WH, Fouque D, Heimburger O, Ritz E: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17: 723-731, 2002 (Pubitemid 34521119)
63. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L: A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19: 1239-1246, 2008
64. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F: Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18: 613-620, 2007 (Pubitemid 46193327)
65. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W: Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168: 1340-1349, 2008 (Pubitemid 351930842)
66. Inaguma D, Nagaya H, Hara K, Tatematsu M, Shinjo H, Suzuki S, Mishima T, Kurata K: Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol 12: 126-131, 2008
67. Wang A, CWK L, JE S, M W, IHS C, SF L: Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: A 3-y prospective cohort study. 87: 1631-1638, 2008
68. Fournier A, Fardellone P, Achard JM, Ghazali A, Pruna A, Esper NE, Morinière P: Importance of vitamin D repletion in uræmia. Nephrol Dial Transplant 14: 819-823, 1999
69. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K: Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3: 1144-1151, 2008
70. Holick MF, Chen TC: Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 87: 1080S-1086S, 2008
71. Brown AJ, Slatopolsky E: Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008 (in press1)
72. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19: 1613-1619, 2008
73. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184, 2004 (Pubitemid 38072630)
74. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003 (Pubitemid 36910023)
75. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005 (Pubitemid 41710323)
76. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858-1865, 2006
77. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007 (Pubitemid 47530570)
78. Drueke TB, McCarron DA: Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. [Editorial] N Engl J Med 349: 496-499, 2003 (Pubitemid 36910029)
79. Olgaard K, Lewin E: Use (or misuse) of vitamin D treatment in CKD and dialysis patients. Nephrol Dial Transplant 23: 1786-1789, 2008; discussion 1789-11783 (Pubitemid 351768193)
80. Palmer S, Strippoli G: Reply: Vitamin D compounds in chronic kidney disease: Change may be needed for good! Nephrol Dial Transplant 23: 1789-1792, 2008
81. Thadhani R: Activated vitamin D sterols in kidney disease. Lancet 371: 542-544, 2008 (Pubitemid 351232019)
82. Tonelli M: Reply. Nephrol Dial Transplant 23: 1792-1793, 2008
83. Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G: Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 19: 566-577, 2006 (Pubitemid 46420075)
84. Moe SM: Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36: 51-62, 2006 (Pubitemid 44050610)
85. Zittermann A, Koerfer R: Protective and toxic effects of vitamin D on vascular calcification: Clinical implications. Mol Aspects Med 2008 (in press1)
86. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA: Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23: 2311-2318, 2008 (Pubitemid 351957604)
87. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005 (Pubitemid 41725117)
88. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI(TM) bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67: 760-771, 2005 (Pubitemid 40139871)
89. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F: The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3: 36-45, 2008
90. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J: Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 1: 305-312, 2006
91. Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A, Soroka SD, Corpier C, Arruda JA, Schwanauer LE, Klassen PS, Olson KA, Block GA: Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68: 10-17, 2007 (Pubitemid 47045487)
92. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263-276, 2006 (Pubitemid 43121329)
93. Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM: Inhibition of parathyroid hormone: A dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 25: 591-595, 2005 (Pubitemid 41816053)
94. Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: A sequential comparison. Am J Kidney Dis 37: 532-543, 2001 (Pubitemid 32195292)
95. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483-1490, 2003 (Pubitemid 36350014)
96. Messa P, Alberti L, Como G, Cerutti R, Mandujano B, Tirelli S, Torresani E, Brezzi B: Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. Nephrol Dial Transplant 22: 2724-2725, 2007 (Pubitemid 47365544)
97. Evenepoel P: Calcimimetics in chronic kidney disease: Evidence, opportunities and challenges. Kidney Int 74: 265-275, 2008 (Pubitemid 352001237)
98. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol 2: 898-905, 2007